Dominican Republic deports dozens of Haitian pregnant women and children in hospital crackdown
In a statement, Dominican authorities said the 135 women and children were taken to a detention center for undocumented migrants on Monday before being sent back to neighboring Haiti.
The sweeping deportations come as one of Dominican President Luis Abinader's controversial immigration measures took effect, requiring staff at National Health Service (SNS) hospitals to ask patients for identification, a letter of employment and proof of residence, for immigration agents at the hospitals to verify.
On Monday, 33 public hospitals braced for the new policy. SNS Director Mario Lama said those hospitals are where up to 80% of public hospital births involving foreign mothers take place.
Dominican authorities say the women and children were detained because of the new protocol. They claimed in a press release that the deportees were treated humanely and with dignity, sent back on comfortable, safe buses only after they were discharged from the hospital and had a medical examination to make sure they were 'free of health risks.'
Rights and health groups have criticized the move.
The Dominican Medical Association said on Instagram such rigid deportation rules for people with medical needs could put their lives at risk.
The Dominican government has stressed that noone would be denied medical care under the new protocol – but rights groups say patients in need of care may steer clear of hospitals in fear of deportation.
'These individuals face immediate deportation after receiving care. This puts people's right to health, privacy, and physical safety at risk—and discourages vulnerable groups, such as pregnant women, children, and survivors of violence, from seeking essential medical treatment,' Amnesty International said on Monday.
Over the past six months Dominican authorities have deported more than 180,000 people back to Haiti, a country plagued by gang violence that has seeped into every aspect of life.
The Dominican Republic, which shares the Island of Hispaniola with its neighbor, has seen an influx of migrants fleeing violence in Haiti – where essential supplies are not keeping up with the population's needs and hundreds of schools have shut down.
Dozens of health facilities have shut down in Haiti because of the insecurity, one of the latest being the University Hospital of Mirebalais. Late last month, gangs stormed the town, setting fire to buildings and posing a risk to the hospital, forcing it to evacuate its staff and patients, according to Partners in Health, the group supporting the hospital.
The United Nations' top Haiti envoy María Isabel Salvador warned this week that Haiti is 'approaching the point of no return.' She added: 'Without timely and decisive international support, the violence will continue to escalate, and Haiti could face total collapse.'
Jessica Hasbun contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Clean and harmonised CRM data vital for AI model training
As healthcare entities move towards the deployment of artificial intelligence (AI) models to streamline patient engagement, being acquitted of good customer relationship management (CRM) system data is of rising importance, an expert has said. In April 2025, the UK National Health Service (NHS) released guidance on the importance of using high-quality data in training AI models. The guidance highlighted that poor quality data can lead to unintended biases and other inaccuracies that may stymy the effectiveness of AI models used for varying functions in healthcare systems. CRM data includes information on patient demographics, individuals' medical history, insurance information, billing details, and more. The consolidation of this data is intended to improve patient engagement, personalise care, and track individuals' medical history. A 2022 report indicated that revenue streams from 44% of healthcare respondents were directly affected bypoor quality CRM data. In addition, 69% of respondents said their organisations did not pursue or complete potentially valuable initiatives due to low-quality CRM data. According to Rachel Mak-McCully, senior data scientist at digital twin developer the cleaning and harmonisation of CRM datasets is not an area that is given enough consideration – despite its significant influence on AI models being deployed in healthcare. 'In thinking about clean data, there's a few issues, including how accurate and comprehensive the data is,' Mak-McCully told Medical Device Network. 'In the US, we have a very fractured medical system, so the information that you get about someone may be quite fractured.' Fractured data can relate to data that is missing because it hasn't been collected at the same time or stored together, Mak-McCully said, or in the sense that it's been measured in different ways. 'Imagine the data cleaning process as a spreadsheet. You might have a lot of different columns that are named differently, but they're the same thing. You want to make sure that all of those are harmonised into the same column,' Mak-McCully said. 'And you want to make sure that the units that you're measuring across a range of different data sources are the same. The ultimate goal is to have a clean, tabular dataset at the end that incorporates all relevant sources of data, so that a single, clean source of data can be used to train your AI model.' Mak-McCully concludes that while there is a lot of talk about the performance of AI models in healthcare and other areas, such as the new benchmarks that have been made, very few people talk about the underlying data. 'For us to clearly communicate what it is that we're doing, the implications of that and for people to understand how data is used, particularly in healthcare, is a really important conversation.' "Clean and harmonised CRM data vital for AI model training" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
CNBC
4 days ago
- CNBC
Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
Eli Lilly on Thursday said it is raising the list price of its blockbuster diabetes drug Mounjaro in the U.K. starting in September, as President Donald Trump pressures drugmakers to lower U.S. drug prices and hike them abroad. In a statement, Eli Lilly said it reached an agreement with the U.K. government to increase the list price of the weekly injection, while "maintaining access" for patients covered under the publicly funded health-care system, the National Health Service, or NHS. Eli Lilly told CNBC that the price hike will not affect the drug's availability under NHS, and it wants to work with the government to boost access. The company added that it does not determine prices that private health-care providers set, but is working with them to ensure access to Mounjaro. In a statement on Thursday, NHS said Mounjaro's list price increase "will not affect NHS commissioning of tirzepatide in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes." Tirzepatide is the active ingredient in Mounjaro and its counterpart for weight loss, Zepbound. Mounjaro's current list price in the UK ranges from £92 (about $124.89) to £122 a month, depending on the dose size, according to Eli Lilly. The drug's new list price will increase to between £133 and £330 starting on Sept. 1. The company added that it is working with certain governments and expects to make pricing adjustments in those countries by that date. In the U.S., the list price for a month's supply of Mounjaro is $1,079.77 before insurance and other rebates. Eli Lilly said it supports the Trump administration's goal of keeping the U.S. the "world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries." "This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US," the company said in the statement. The announcement comes after Trump in July sent separate letters to 17 drugmakers, including Eli Lilly, calling on them to take steps to lower drug prices by Sept. 29. The move built on the president's executive order in May reviving a controversial plan – the "most favored nation" policy – that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad. U.S. prescription drug prices are two-to-three times higher on average than those in other developed nations – and up to 10 times more than in certain countries, according to the Rand Corp., a public policy think tank. Trump has said he wants to narrow that gap to stop Americans from being "ripped off." Eli Lilly's announcement on Thursday comes as the industry braces for Trump's planned tariffs on pharmaceuticals imported into the U.S. In its statement, the company said it opposes those tariffs, arguing they will "raise costs, limit patient access, and undermine American leadership, especially for companies already investing heavily in domestic manufacturing." In recent months, Eli Lilly was among several drugmakers to announce new plans to invest in U.S. manufacturing sites.
Yahoo
6 days ago
- Yahoo
World-first gonorrhea vaccine being rolled out in England
On 4 August 2025, the UK's National Health Service (NHS) began the roll-out of the world's first gonorrhea vaccination programme. Gonorrhea is a common sexually transmitted infection (STI) that is often asymptomatic but can be characterised by unusual discharge from the penis or vagina and pain when urinating. Gay and bisexual men with a recent history of multiple sexual partners or bacterial STIs in the past 12 months are now eligible for a free vaccine. The vaccine, 4CMenB, is already being used to protect against meningitis B. According to the UK's Department of Health and Social Care, offering it to vulnerable populations will protect 100,000 people from the gonorrhea infection over the next decade, relieving pressure on the NHS's sexual health services and saving an estimated £7.9 million ($10.5 million). In 2023, recorded cases of gonorrhea reached an all-time peak in the UK with 85,000 diagnoses — three times higher than in 2012, emphasising the rapid growth in incidence, according to the UK Health Security Agency. Gonorrhea is treated with an antibiotic injection, which typically relieves symptoms in a few days. However, antibiotic-resistant strains have begun to emerge, meaning that rollout of the vaccine has come at a crucial time. According to the UK's Minister for Public Health, Ashley Dalton: 'Rolling out this world-leading gonorrhea vaccination programme in sexual health clinics in England represents a major breakthrough in preventing an infection that has reached record levels. This government's world-first vaccination programme will help turn the tide on infections, as well as tackling head-on the growing threat of antibiotic resistance.' Physicians need to emphasise that while vulnerable populations, such as gay and bisexual men, are being encouraged to seek vaccination, these groups should be reminded that precautions such as condoms should still be used to prevent the transmission of other sexually transmitted diseases. GlobalData epidemiologists initially anticipated that the diagnosed incident cases of gonorrhea among men and women of all ages in the UK would increase from 96,000 in 2025 to 99,000 in 2033. However, if a significant proportion of the vulnerable population receives the vaccination, it is expected that diagnosed incident cases will decline, benefiting patient outcomes, NHS spending and the prevention of antibiotic resistance. "World-first gonorrhea vaccine being rolled out in England" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
